ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
8.57
-0.16
(-1.83%)
Cerrado 02 Diciembre 3:00PM
8.60
0.03
(0.35%)
Fuera de horario: 3:33PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
8.57
Postura de Compra
8.50
Postura de Venta
9.12
Volume Operado de la Acción
1,131,457
8.48 Rango del Día 8.86
3.08 Rango de 52 semanas 14.84
Capitalización de Mercado [m]
Precio Anterior
8.73
Precio de Apertura
8.79
Última hora de negociación
Volumen financiero
US$ 9,779,356
Precio Promedio Ponderado
8.6432
Volumen promedio (3 m)
2,834,344
Acciones en circulación
71,124,625
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-6.89
Beneficio por acción (BPA)
-1.24
turnover
426k
Beneficio neto
-88.45M

Acerca de Altimmune Inc

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Altimmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was US$8.73. Over the last year, Altimmune shares have traded in a share price range of US$ 3.08 to US$ 14.84.

Altimmune currently has 71,124,625 shares in issue. The market capitalisation of Altimmune is US$620.92 million. Altimmune has a price to earnings ratio (PE ratio) of -6.89.

Flujo de Opciones Altimmune (ALT)

Flujo General

Optimista

Prima Neta

27k

Calls / Puts

100.00%

Comp. / Vent.

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ALT Últimas noticias

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide...

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and...

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.151.781472684098.429.238.2321958128.62024949CS
41.7525.65982404696.8211.166.4542955958.37420029CS
122.1533.48909657326.4211.165.8628343447.64523611CS
261.6624.0231548486.9111.165.27530158597.13239453CS
525.46175.5627009653.1114.843.0855331827.8297008CS
156-2.12-19.831618334910.6923.492.0928564918.10903896CS
2606.88407.1005917161.6935.11.624725889.71546034CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BSLKBolt Projects Holdings Inc
US$ 0.71
(139.86%)
80.81M
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
205.02M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
PASGPassage Bio Inc
US$ 1.13
(69.52%)
15.44M
EPOWSunrise New Energy Company Ltd
US$ 1.06
(45.21%)
314.9k
APLTApplied Therapeutics Inc
US$ 2.03
(-76.31%)
42.74M
TGLTreasure Global Inc
US$ 0.2944
(-29.08%)
1.83M
PROCProcaps Group SA
US$ 1.51
(-27.75%)
98.71k
SHOTWSafety Shot Inc
US$ 0.104
(-20.00%)
1.43k
MONDMondee Holdings Inc
US$ 0.7102
(-19.59%)
297.61k
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
202.48M
NVDANVIDIA Corporation
US$ 138.25
(2.15%)
140.34M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
RGTIRigetti Computing Inc
US$ 3.05
(27.08%)
115.6M
MARAMARA Holdings Inc
US$ 27.42
(1.86%)
88.39M

ALT Discussion

Ver más
Mark102 Mark102 4 meses hace
As promised I don't see any dilution in the filing. Shorts are in trouble
👍️0
Mark102 Mark102 4 meses hace
Float is Locked and over 23 million naked shares Short. Shorts have failed Miserably at shaking out Retail and can't cover without a massive loss.
Price Targets
Partner 50 to 75
Buyout 140 to 200
👍️0
Mark102 Mark102 4 meses hace
https://forextv.com/top-news/altimmune-announces-publication-of-clinical-study-of-pemvidutide-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-in-journal-of-hepatology/
👍️0
Mark102 Mark102 5 meses hace
IT'S HAPPENING
👍️0
Mark102 Mark102 5 meses hace
Beautiful Bull Flag
👍️0
girlfriend girlfriend 5 meses hace
Well....not quite but a nice pop anyways this week.
👍️0
Mark102 Mark102 5 meses hace
Last chance next week above 20
👍️0
Mark102 Mark102 5 meses hace
It's being shorted by its competitors not tutes. . An advisor from Lilly is making the presentations of pemvi data this weekend.its what you know not what some want you to believe.
👍️0
brfv11 brfv11 6 meses hace
Not a chance at 60. Shorts are playing this one perfectly. Investors are just not interested in ALT. Good luck.
👍️0
Mark102 Mark102 6 meses hace
Shorts looking weak and vulnerable today any trading room with the funds could squeeze this to 60 easy
👍️0
Mark102 Mark102 6 meses hace
Goldman Sachs been short stacking here for months and they are hosting the fireside tomorrow. I'm loading up today
👍️0
brfv11 brfv11 6 meses hace
Time to admit shorty got this one right! This one is going all the way down.
Merger/ buyout what a joke.
👍️0
akamaii akamaii 6 meses hace
This Wednesday we hope data rules. Give us data 📈
👍️0
akamaii akamaii 7 meses hace
Going long for a year 75 target or 50 plus
👍️0
Mt. Blanc Mt. Blanc 7 meses hace
So much for my ALT prediction.

The stock slipped to $7 and may be cratering more since it's getting no love.

Maybe ALT is a $5 stock or lower if buyers aren't interested.

mb
👍️0
Mt. Blanc Mt. Blanc 8 meses hace
Radar. ALT $11- $12

Getting picked up.

mb
👍️0
Monksdream Monksdream 8 meses hace
ALT over $10
Next day settlement begins 5/28 per SEC mandate
👍️0
Monksdream Monksdream 8 meses hace
ALT 10Q due 3/27
Next day settlement begins 5/28
👍️0
saigai saigai 9 meses hace
patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
👍️0
Mark102 Mark102 9 meses hace
Buyout? Partnership? In less than 9 trading days we will find out.
👍️0
Mark102 Mark102 9 meses hace
BUCKLE UP. going to break 15 soon
👍️0
saigai saigai 9 meses hace
a good read
https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
👍️0
saigai saigai 9 meses hace
slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
👍️0
Mt. Blanc Mt. Blanc 9 meses hace
ALT @ $12?

Interesting

mb
👍️0
saigai saigai 9 meses hace
institutional ownership from nasdaq site
https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
👍️0
saigai saigai 10 meses hace
big volume wrong direction for now
👍️0
saigai saigai 10 meses hace
a good read
https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
👍️0
saigai saigai 10 meses hace
and a few more...
👍️0
saigai saigai 10 meses hace
you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
👍️0
saigai saigai 10 meses hace
driving me nutz but i wont sell this until !!!
👍️0
murocman murocman 11 meses hace
Post from another board relevant to ALT:

GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
👍️0
AGORDON AGORDON 11 meses hace
Altimmune, Inc.
(Nasdaq - ALT) $12/share
Market cap = $644M
Cash = $140M
Cash Burn rate = ($76)/Y
Catalysts:
Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
👍️0
Mark102 Mark102 11 meses hace
I was wrong ALT is attending the JPM Let's get this deal done.
👍️0
saigai saigai 11 meses hace
thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
👍️0
Mark102 Mark102 11 meses hace
Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
Now why is ALT not attending the JPM conference this week? Stay tuned
👍️0
saigai saigai 11 meses hace
im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
👍️0
Mark102 Mark102 11 meses hace
Float is locked, tutes trying to shake few out but this is a done deal IMO
👍️0
saigai saigai 11 meses hace
this is a powder keg...
👍️0
saigai saigai 11 meses hace
i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
👍️0
Mark102 Mark102 11 meses hace
Been Holding since 6. Buyout or partnership is imminent.
👍️0
1hot toddy 1hot toddy 11 meses hace
HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
👍️0
Bud-Wiser Bud-Wiser 11 meses hace
Nice comeback today -I’m back in
👍️0
1hot toddy 1hot toddy 11 meses hace
WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BABY MONSTER HERE
👍️0
eyeownu eyeownu 11 meses hace
got dammmmmmmmmmm. oprah must be buying out the company
👍️0
1hot toddy 1hot toddy 11 meses hace
WOOOOOOW 10,000 SHARE BUY $110,000 BUY $$$$$$$$$$$$$$$$
MONSTER WEIGHT LOSS CO HERE
👍️0
Mark102 Mark102 11 meses hace
Next Gap to 19 to fill. PT 60 to 100 on a buyout
👍️0
1hot toddy 1hot toddy 11 meses hace
WOOOOOOOOOOOW 21000 SHARE BUY OVER $150,000 BUY . KILLER WEIGHT LOSS HERE $$$$$$$$$$$
👍️0
eyeownu eyeownu 11 meses hace
rallys over IMO. end of year.. could be wrong tho!
👍️0
1hot toddy 1hot toddy 11 meses hace
WOOOOOOOOOOW 11000 SHARE BUY $90000 BUY WEIGHT LOSS RESULTS GREAT $$$$$
👍️0
1hot toddy 1hot toddy 11 meses hace
HUGE BUYS 8000 SHARES PLUS BUNCH OF 4000 SHARE BUYS $$$$$$$$$
👍️0

Su Consulta Reciente

Delayed Upgrade Clock